Bourne Lent Asset Management Inc. maintained its stake in Bristol-Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 7,820 shares of the biopharmaceutical company’s stock at the end of the second quarter. Bourne Lent Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $436,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Blue Chip Partners Inc. boosted its stake in Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares in the last quarter. Keel Point LLC boosted its stake in Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 18 shares in the last quarter. Staley Capital Advisers Inc. boosted its stake in Bristol-Myers Squibb by 0.3% in the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 24 shares in the last quarter. Shayne & CO. LLC boosted its stake in Bristol-Myers Squibb by 0.7% in the first quarter. Shayne & CO. LLC now owns 4,017 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 27 shares in the last quarter. Finally, Founders Capital Management LLC boosted its stake in Bristol-Myers Squibb by 0.7% in the first quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 29 shares in the last quarter. 69.68% of the stock is owned by hedge funds and other institutional investors.

Shares of Bristol-Myers Squibb Company (NYSE BMY) traded down 0.62% during mid-day trading on Friday, hitting $56.42. 4,809,885 shares of the stock were exchanged. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $60.45. The stock has a 50-day moving average price of $55.95 and a 200 day moving average price of $54.96. The firm has a market cap of $92.52 billion, a price-to-earnings ratio of 20.61 and a beta of 1.17. Bristol-Myers Squibb also saw unusually large options trading activity on Thursday. Stock investors acquired 781 put options on the stock. This represents an increase of approximately 117% compared to the typical daily volume of 360 put options.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter in the prior year, the company earned $0.69 EPS. Bristol-Myers Squibb’s quarterly revenue was up 5.6% on a year-over-year basis. On average, equities research analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were issued a $0.39 dividend. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 annualized dividend and a yield of 2.76%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.

WARNING: “Bristol-Myers Squibb Company (BMY) Position Maintained by Bourne Lent Asset Management Inc.” was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/08/19/bristol-myers-squibb-company-bmy-position-maintained-by-bourne-lent-asset-management-inc.html.

A number of brokerages recently issued reports on BMY. Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Wednesday. BMO Capital Markets reissued an “underperform” rating and set a $47.00 price target (down from $51.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, July 26th. Leerink Swann lowered their price target on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $62.12.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now owns 18,000 shares in the company, valued at $1,006,920. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.23% of the stock is currently owned by corporate insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.